Free tool
FAERS Monitor: Syndros
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205525 or its brand name (Syndros, Dronabinol). Reports on generic versions are filed under their own applications.
Reports
5,133
Serious
3,836
75% of reports
Hospitalization
1,804
Death reported
1,169
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea485
- fatigue420
- off label use388
- diarrhoea387
- death383
- toxicity to various agents341
- drug abuse309
- vomiting281
- decreased appetite275
- pain253
- weight decreased237
- drug screen positive225
- dyspnoea223
- drug ineffective210
- asthenia203
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 12 |
| 2005 | 16 |
| 2006 | 22 |
| 2007 | 16 |
| 2008 | 16 |
| 2009 | 27 |
| 2010 | 36 |
| 2011 | 58 |
| 2012 | 60 |
| 2013 | 80 |
| 2014 | 136 |
| 2015 | 211 |
| 2016 | 246 |
| 2017 | 338 |
| 2018 | 477 |
| 2019 | 512 |
| 2020 | 439 |
| 2021 | 407 |
| 2022 | 415 |
| 2023 | 465 |
| 2024 | 495 |
| 2025 | 397 |
| 2026 | 252 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,026 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug screen positiveSignal | 225 | 120.0 | 105.4 | 25,701 |
| drug abuseSignal | 309 | 15.3 | 13.7 | 4,105 |
| toxicity to various agentsSignal | 341 | 8.3 | 7.5 | 2,195 |
| decreased appetiteSignal | 275 | 4.9 | 4.3 | 847 |
| weight decreasedSignal | 237 | 3.5 | 3.1 | 422 |
| nauseaSignal | 485 | 2.5 | 2.3 | 457 |
| diarrhoeaSignal | 387 | 2.5 | 2.2 | 343 |
| vomitingSignal | 281 | 2.4 | 2.2 | 245 |
| astheniaSignal | 203 | 2.2 | 1.9 | 136 |
| fatigueSignal | 420 | 2.2 | 2.0 | 288 |
| death | 383 | 1.8 | 1.7 | 147 |
| off label use | 388 | 1.8 | 1.7 | 148 |
| pain | 253 | 1.7 | 1.5 | 72 |
| dyspnoea | 223 | 1.6 | 1.4 | 53 |
| drug ineffective | 210 | 0.7 | 0.6 | 41 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.